Natco Pharma receives USFDA EIR for Vizag facility
Andhra Pradesh: Natco Pharma Limited has announced the successful closure of inspection and receipt of an Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration (USFDA) for its drug formulations manufacturing facility at Visakhapatnam (Vizag) Andhra Pradesh, India."The inspection conducted during the period from 24th March to 30th March 2020", Natco said in a...
Andhra Pradesh: Natco Pharma Limited has announced the successful closure of inspection and receipt of an Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration (USFDA) for its drug formulations manufacturing facility at Visakhapatnam (Vizag) Andhra Pradesh, India.
"The inspection conducted during the period from 24th March to 30th March 2020", Natco said in a filing
Natco Pharma Limited was incorporated in Hyderabad in the year 1981 with an initial investment of INR 3.3 million.
The Company has seven manufacturing facilities spread across India with modern research laboratories, capabilities in New Drug Development, etc.
Read also: Natco Pharma gets USFDA nod for Vizag Formulation Facility
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd